Cancer Treatment Gets a Boost with Radixact System in Mumbai
A Mumbai hospital has introduced the Radixact® Treatment Delivery System, a new radiation therapy technology aimed at improving accuracy in cancer treatment and reducing harm to healthy tissue.
The system combines real-time imaging with adaptive targeting, allowing doctors to adjust radiation delivery as the patient's body moves—such as during breathing. A built-in CT scanner helps ensure the tumor remains accurately targeted throughout the procedure.
According to the hospital, this upgrade is part of ongoing efforts to improve cancer care through more precise, individualized treatment. The system is capable of treating a variety of cancers and is designed to deliver higher doses of radiation with fewer side effects.
The hospital has also invested in genomic testing and precision oncology infrastructure. A 500-gene cancer panel is being used to support more tailored treatment plans based on a tumor's genetic profile.
precision and efficiency.
Dr Santosh Shetty, Executive Director and CEO of Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute said, 'At Kokilaben Hospital, we are constantly pushing the boundaries of medical innovation to ensure our patients receive the most advanced and effective treatment. The adoption of the globally acclaimed Radixact® system marks a major leap forward in our commitment to delivering world-class cancer care. As a centre that continues to be recognized for its leadership in oncology, we are proud to bring one of the most sophisticated radiation technologies to India. This upgrade reaffirms our dedication to adopting global standards that improve both clinical outcomes and quality of care .'
The adoption of the Radixact system comes amid a growing cancer burden in India. Health experts say timely access to accurate diagnosis and targeted treatment remains a challenge for many patients, and that such technologies could help improve survival rates and reduce complications.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Wall Street sees new obesity pills as priced near Wegovy and Zepbound
By Maggie Fick and Bhanvi Satija SEATTLE (Reuters) -U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. U.S. list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4% after 72 weeks in a trial. That compares with weight loss of 15% for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21%. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is "probably going to come on par with the current drugs today or slightly lower," Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. GROWING CASH PAY U.S. doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40% of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce U.S. prices. Novo declined to comment on pricing, pointing to August 6 comments by David Moore, its U.S. operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. MANUFACTURING VOLUME A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the U.S. market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. "It's all about scale and pricing," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. A weekly regimen of the pill requires about 75 times more active ingredient than the highest-dose weekly Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. "Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy," Andersen added.
Yahoo
an hour ago
- Yahoo
‘Ozempic for dogs' may be the next big thing in pet health
With the runaway success of drugs like Ozempic and Mounjaro effectively helping humans slim down, researchers and biotech firms are now sniffing out a new frontier: weight-loss drugs for dogs. With up to 60 per cent of dogs in the UK estimated to be overweight or obese, the market for such drugs could be considerable. Okava, a San Francisco-based bio-pharma company which specialises in pet health, is planning to run trials for a drug designed to mimic the effects of Ozempic, with the goal to produce an implant-version for dogs, which lasts six-months at a time. According to estimates on the company's website, the current market for such a product could be worth $10bn, and they hope to have a canine weight-loss drug available as early as 2028 or 2029. In human weight-loss drugs, the active ingredient in Mounjaro is called tirzepatide, and in Ozempic, it is semaglutide. Both work in similar ways, mimicking a natural hormone called GLP-1. This hormone regulates blood sugar and appetite, ultimately leading people to feel fuller longer and reducing food intake. The challenge for biotech firms is to reproduce that effect in dogs – a species well-known for practically limitless gorging. The hope is that an Ozempic-style drug may reduce dogs' begging behaviour, which many owners find it difficult to resist rewarding. Often, lack of appetite in dogs is associated with illness, meaning developing an effective drug that doesn't appear to make pets seem unwell is a fine balance. One such drug, named Slentrol, was launched in 2007, but did not sell well, partly due to how owners' perceived their pets behaviour when on the medication. Okava's planned implant, called OKV-119, contains a GLP-1 mimic called exenatide. Michael Klotsman, Okava's chief executive, said he hoped dogs' behavioural changes from OKV-119 would be quite different from illness-related appetite loss. 'What owners should expect to see is their pet eating appropriate portions without the previous food obsession – they'll still eat regularly and show interest in meals, just without the excessive begging, scavenging or gulping behaviour,' he told The Guardian. But not all tails are wagging. Vets have suggested that in most cases, dog owners would be better off avoiding obesity in their dogs through more exercise and by restricting their pets' diets. Caroline Allen, Chief Veterinary Officer at the RSPCA told The Independent: 'A healthy diet and exercise is the best way to keep our pets happy and well but we understand that owners can sometimes struggle to manage their pets' weight. There is currently little information about proposed weight-loss implants or vaccinations for animals, and owners shouldn't rely on them becoming available. 'Before resorting to these sorts of interventions, owners should seek help from their vet about how to reduce their pet's weight with a good diet and providing lots of opportunities to exercise and play in ways that their pet will enjoy." She added: 'It may be that weight loss jabs or implants may have a role to play in future in very limited circumstances where animals are clinically unwell, but the best thing we can do is set healthy habits from the start so our pets can live the best life possible.'
Fox News
an hour ago
- Fox News
Doctors divided over new diet trend that has babies licking butter and gumming ribeye steak
Some parents are swapping puréed fruits and vegetables, oatmeal and yogurt for butter, bone broth, sardines and chicken liver as part of a controversial new "carnivore baby" trend – but experts are urging caution. As carnivore and protein-packed diets gain popularity among adults, many of whom are rejecting ultra-processed foods, some are passing them on to their kids. Some doctors are even sharing that they feed their babies meat-forward meals, The Wall Street Journal recently reported. Facebook groups are catering to carnivore families and parents are sharing tips on school lunches – rotisserie chicken, pork rinds and hard-boiled eggs among them. Meanwhile, others seek insight on trying to conceive while eating only meat. Dariya Quenneville, a mother in Ontario, Canada, told the publication that she started feeding her daughter raw egg yolks and puréed chicken liver as soon as she could eat solid foods and then moved on to sardines, bone broth ice pops, leg of lamb, beef heart and tongue. Lorraine Bonkowski, a registered dietitian from Michigan, and her one-year-old daughter are both on carnivore diets, Bonkowski told The Wall Street Journal. The little girl licks butter off a spoon, gets a bottle full of bone broth and uses her four teeth to gum ribeye steak. Bonkowski said she introduced fruit to her daughter's diet because her baby was getting constipated from all the meat. The Centers for Disease Control and Prevention (CDC) recommends feeding children over 12 months a variety of fruits, vegetables, whole grains, proteins and dairy products. While the carnivore trend has been firing up – U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. recently shared that he follows it – others have been pushing it for years. In 2021, Dr. Robert Cywes, a Florida-based pediatrician, and his wife, Janae, said in a YouTube video that they started giving their son meat at 4 months old. His first real meal, they said, was a ribeye steak. "From a functional perspective, from a milestone perspective, he's right on target," Cywes claimed at the time. Dr. Shawn Baker, the Washington-based author of the book "The Carnivore Diet," boasted in a YouTube video last year that his baby ate a carnivore diet for six months, was walking at 10 months old and grew to be "strong and tall." "The first food for a baby, when it was ready to wean off the breast, was meat." Some doctors claim the practice has been used for centuries. "This is actually the original way that humans fed their babies 100 years ago, 500 years ago, 5,000 years ago," Dr. Ken Berry, a family physician in Tennessee, told Fox News' Dana Perino on "America's Newsroom." "The first food for a baby, when it was ready to wean off the breast, was meat … gnawing on a bone," Berry said. Meat ensures that babies get certain nutrients, vitamins, minerals, fatty acids and amino acids, he added, slamming puffs and other kids' snacks as "junk." However, Berry did recommend moderation by pairing meat with whole foods like berries. Fox News' senior medical analyst Dr. Marc Siegel said introducing kids to meat gets them plenty of protein and iron, yet without fruits and vegetables, the diet can become an "addiction." "It's a high-inflammation diet, which means later on, when you get to be an adult, you end up with heart disease, you end up with cancer, you end up with diabetes and you end up with obesity," Siegel said on "The Faulkner Focus." "This is a very bad diet to get addicted to as a kid," he said. Lauren Manaker, a registered dietitian nutritionist and mom in South Carolina, told Fox News Digital that while the carnivore diet provides "many options" that are "fantastic for babies," she said it "isn't ideal for little ones." "Babies need a variety of nutrients to grow and thrive, and a diet that cuts out or limits plant-based foods like fruits, veggies and grains can leave some big nutritional gaps," she cautioned.
